Stay updated on Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-05-01T05:43:09.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has undergone significant content removal, particularly regarding a study on HER2 Positive Breast Cancer, including detailed inclusion and exclusion criteria for participants. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.
    Difference
    11%
    Check dated 2025-04-16T14:41:01.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 17, 2025. However, the changes do not significantly impact core content or important information.
    Difference
    0.1%
    Check dated 2025-04-09T09:37:14.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:29:22.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The webpage has updated its date references, removing older dates and adding new ones for 2025, indicating a refresh of the content's timeliness.
    Difference
    0.8%
    Check dated 2025-03-18T08:54:36.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-24T20:42:09.000Z thumbnail image

Stay in the know with updates to Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.